Long silent, Parkinson’s disease could now be detected well before the onset of tremors thanks to a simple blood test. Behind this breakthrough is a biological signature identified in late January by a team of researchers, capable of signaling the earliest stage of the disease, sometimes 10 to 20 years before diagnosis.
- A biological signature detectable in the blood could reveal Parkinson’s disease up to 20 years before the first tremors appear.
- This discovery is based on the analysis of genes involved in DNA repair and the cellular stress response.
- The identified markers make it possible to detect the very earliest phases of the disease with high accuracy.
- Once Parkinson’s is diagnosed, these signals become far less distinctive, confirming their early role.
- Ultimately, this breakthrough could pave the way for an accessible blood screening test and earlier intervention.
Parkinson’s: a disease that progresses in the shadows
More than 10 million people worldwide are living with Parkinson’s. This chronic neurodegenerative disorder is characterized by the progressive destruction of dopamine-producing neurons, which are essential for movement control. When these cells disappear, the well-known symptoms emerge: resting tremors, slowed movements, muscle rigidity, and balance problems.
But these visible signs are only the tip of the iceberg. The disease begins developing long before they appear. This so-called “prodromal” phase can last years—sometimes decades. REM sleep behavior disorder, loss of smell, severe constipation, and mood fluctuations are among the warning signs that precede motor symptoms.
By the time a diagnosis is made, more than half of the brain’s dopaminergic neurons have already been destroyed. That is the central challenge of current research: identifying the disease earlier, before irreversible brain damage occurs.
A biological signature detectable in the blood
This major scientific advance comes from a Scandinavian research team whose findings were published in the journal npj Parkinson’s Disease.
The researchers focused on two cellular mechanisms believed to be involved very early in the disease process: DNA repair and the cellular stress response.
The principle is straightforward. Our cells have internal systems that correct damage and protect themselves when under stress. By analyzing the activity of thousands of genes in blood samples from healthy volunteers, individuals in the prodromal phase, and diagnosed patients, scientists identified a pattern of gene activity specific to the earliest stages of Parkinson’s.
This signature, involving genes such as ERCC6, PRIMPOL, NEIL2, and NTHL1, can distinguish individuals in the early phase with up to 89% accuracy for certain DNA repair mechanisms and 91% accuracy for stress-response pathways.
Notably, these markers become far less discriminating once the disease is established, as if the biological alarm only sounds within a specific window, 10 to 20 years before the first tremors.
A paradigm shift in screening
Currently, there is no validated test to screen for Parkinson’s disease on a large scale before symptoms appear. Other approaches are being explored, such as brain imaging, cerebrospinal fluid analysis, and the detection of alpha-synuclein. However, these methods remain complex, costly, or invasive.
The prospect of a simple blood test could change everything. According to the researchers, tools based on this biological signature could begin to be tested within healthcare systems within five years. The goal would be to identify at-risk individuals earlier, particularly those with REM sleep behavior disorder or strong family predisposition.
For the fields of aging and prevention, the stakes are high. Detecting the disease before massive neuronal loss would open the door to neuroprotective treatment trials at a stage when they might genuinely preserve brain function.
Middle Ground Between scientific hope and medical caution
These results must still be confirmed in larger and more diverse populations. Gene expression in blood does not perfectly mirror what occurs in the brain, so caution remains essential.
Nevertheless, this research marks a turning point: moving from symptom-based diagnosis to biology-based detection. For the millions already affected worldwide, prospect of early screening is already reshaping how specialists envision the future of care.
Parkinson’s disease may no longer be diagnosed only when it becomes visible. In the future, it may be detected just as it begins to act.
Published by the Editorial Staff on